abstract |
The present invention relates to amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2- (1- (2-fluorobenzyl) -5- (isoxazole-3 -Yl) -1H-pyrazol-3-yl) pyrimidin-4-yl) amino) methyl) propan-2-ol (compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions comprising them and medical oral unit dosage forms and their use. |